巴瑞替尼调控巨噬细胞极化减轻硬皮病小鼠肺纤维化

王郸丹; 徐璐璐; 张劼

doi:10.16016/j.2097-0927.202306114

您当前的位置：

首页 >

文章列表页 >

巴瑞替尼调控巨噬细胞极化减轻硬皮病小鼠肺纤维化

基础医学 | 更新时间：2026-01-09

- 巴瑞替尼调控巨噬细胞极化减轻硬皮病小鼠肺纤维化
- Baricitinib attenuates pulmonary fibrosis in scleroderma mice by regulating macrophage polarization
- 陆军军医大学学报 2024年46卷第2期页码：128-138
- 作者机构：
  
  1.646000 四川泸州，西南医科大学附属医院呼吸与危重症医学科
  2.400014 重庆，重庆市人民医院老年病科
- 作者简介：
  
  [张劼，E-mail: zhangjie_cq@outlook.comZHANG Jie, E-mail: zhangjie_cq@outlook.com
- 基金信息：
  
  重庆自然科学基金(cstc2021jcyj-msxmX1129);重庆市科卫联合医学科研项目(2020GDRC012c);重庆市中青年医学高端人才工作室(2021-102);重庆市老年疾病临床研究中心项目(2020-126)
- DOI：10.16016/j.2097-0927.202306114
  中图分类号： R593.25;R967;R986
- 收稿：2023-06-29，
  
  修回：2023-08-19，
  
  纸质出版：2024-01-30
- 稿件说明：
移动端阅览
王郸丹, 徐璐璐, 张劼. 巴瑞替尼调控巨噬细胞极化减轻硬皮病小鼠肺纤维化[J]. 陆军军医大学学报, 2024,46(2):128-138.

Dandan WANG, Lulu XU, Jie ZHANG. Baricitinib attenuates pulmonary fibrosis in scleroderma mice by regulating macrophage polarization[J]. Journal of Army Medical University, 2024, 46(2): 128-138.
王郸丹, 徐璐璐, 张劼. 巴瑞替尼调控巨噬细胞极化减轻硬皮病小鼠肺纤维化[J]. 陆军军医大学学报, 2024,46(2):128-138. DOI： 10.16016/j.2097-0927.202306114.

Dandan WANG, Lulu XU, Jie ZHANG. Baricitinib attenuates pulmonary fibrosis in scleroderma mice by regulating macrophage polarization[J]. Journal of Army Medical University, 2024, 46(2): 128-138. DOI： 10.16016/j.2097-0927.202306114.

摘要

目的

明确巴瑞替尼能否通过抑制酪氨酸蛋白激酶2(Janus kinase

JAK2)/信号传导与转录激活因子3(signal transducer and activator of transcription

STAT3)调控巨噬细胞极化，从而减轻硬皮病小鼠肺纤维化程度。

方法

30只8周雌性C57BL/6小鼠按随机数字表法分为3组: 对照组(Ctl组，

=6)、硬皮病组(SSc组，

=12)和硬皮病+巴瑞替尼组(SSc+Ba组，

=12)。SSc和SSc+Ba组小鼠背部皮下注射博来霉素(7.5 mg/kg)，SSc+Ba组小鼠胃内灌注巴瑞替尼(5 mg/kg)。采用ELISA检测血浆中炎症因子白介素(interleukin

IL)-1β、IL-4、IL-6、IL-10浓度，HE、Masson染色评估皮肤真皮层厚度和肺组织病变及胶原含量，RT-PCR分析肺组织中炎症因子(IL-1β、IL-4、IL-6、IL-10)mRNA水平，Western blot分析肺组织中巨噬细胞标志物CD86、CD163及JAK2/STAT3的蛋白表达水平，流式细胞术检测F4/80、CD86和CD163以明确小鼠脾脏巨噬细胞极化情况，免疫荧光检测肺组织中CD86和CD163以明确肺组织中巨噬细胞极化情况。

结果

与Ctl组相比，SSc组小鼠注射部位皮肤真皮层增厚(

0.001)，改良肺纤维化评分升高(

0.001)，皮肤和肺组织胶原增多(

0.001)。SSc+Ba组小鼠上述表现均有不同程度的减轻(

0.01)。与Ctl组相比，SSc组小鼠血浆中促炎因子IL-1β(

0.05)和IL-6(

0.001)浓度以及肺组织中上述两种因子的mRNA(

0.05)水平明显上调。巴瑞替尼降低上述因子浓度(

0.01)和肺组织中mRNA(

0.01)水平。SSc组小鼠肺中JAK2/STAT3表达升高(

0.01)，巴瑞替尼降低上述蛋白的表达(

0.05)。Western blot和免疫荧光检测结果均表明: 与Ctl组相比，SSc组肺中CD86蛋白(M1巨噬细胞标志物)表达升高(

0.01)，CD163蛋白(M2巨噬细胞标志物)表达降低(

0.05)。SSc+Ba组肺中CD86蛋白表达降低(

0.05)，CD163蛋白表达升高(

0.05)。流式细胞术检测结果表明，SSc组脾脏巨噬细胞中F4/80

CD86

CD163

的M1型巨噬细胞比例升高(

.001)，F4/80

CD86

CD163

的M2型巨噬细胞比例降低(

0.01)。SSc+Ba组中，M1细胞比例降低(

0.01)，M2细胞比例升高(

0.001)。

结论

巴瑞替尼通过靶向JAK2/STAT3信号通路抑制M1巨噬细胞极化，来减轻SSc小鼠肺纤维化程度。

Abstract

Objective

To determine whether baricitinib regulates macrophage polarization through Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) signaling pathway to reduce the severity of pulmonary fibrosis in mice with scleroderma.

Methods

Thirty 8-week-old female C57BL/6 mice were randomly divided into control group (Ctl

=6)

scleroderma group (SSc

=12) and scleroderma+baricitinib group (SSc+Ba

=12). The mice of the SSc and SSc+Ba group were inflicted with a subcutaneous injection of 7.5 mg/kg bleomycin in the back

and an intragastric gavage of 5 mg/kg baricitinib. ELISA was used to detect the plasma levels of inflammatory factors

IL-1β

IL-4

IL-6 and IL-10. HE staining and Masson staining were employed to determine the thickness of skin dermis and pathological changes and collagen content in lung tissue. The mRNA expression of IL-1β

IL-4

IL-6 and IL-10 in lung tissue was measured by RT-PCR

and the protein levels of macrophage markers CD86

CD163 and JAK2/STAT3 in lung tissue were detected by Western blotting. Afterwards

flow cytometry was applied for the expression of F4/80

CD86 and CD163 to determine the polarization of macrophages. Immunofluorescence assay was used to detect CD86 and CD163 to clarify the polarization of macrophages in lung tissue.

Results

Compared with the Ctl group

the dermis at the injection site in the back was significantly thickened (

0.001)

the score of pulmonary fibrosis was obviously increased (

0.001)

and the coll

agen content in skin and lung tissue was notably elevated in the SSc group (

0.001). The above changes were alleviated to varying degrees in the SSc+Ba group (

0.01). The SSc group had significantly higher plasma levels of IL-1β (

0.05) and IL-6 (

0.001) as well as elevated their mRNA levels in lung tissue (

0.05) than the Ctl group. Baritinib treatment decreased the plasma concentrations of the above factors (

0.01) and their mRNA levels in lung tissue (

0.01). JAK2/STAT3 was highly expressed in the SSc group (

0.01)

and baricitinib reduced the activation of JAK2/STAT3 pathway (

0.05). Western blotting and immunofluorescence assay indicated that CD86 protein (marker of M1 macrophages) was highly expressed (

0.01) and CD163 protein (marker of M2 macrophages) was in low expression (

0.05) in lung tissue in the SSc group than the Ctl group. In the SSc+Ba group

CD86 protein was reduced (

0.05) and CD163 protein was increased (

0.05) in lung tissue. Flow cytometry showed that the proportion of F4/80

CD86

CD163

M1 macrophages in the spleen was increased (

0.001)

and the proportion of F4/80

CD86

CD163

M2 macrophages was decreased in the SSc group when compared with Ctl group (

0.01). In the SSc+Ba group

the proportion of M1 was decreased (

0.01)

and that of M2 was increased (

0.001).

Conclusion

Baricitinib inhibits M1 macrophage polarization through JAK2/STAT3 signaling pathway

thus reducing the fibrosis of lung tissue in SSc mice.

关键词

Keywords

references

DENTON C P, KHANNA D. Systemic sclerosis[J]. Lancet, 2017, 390(10103): 1685-1699. DOI: 10.1016/S0140-6736(17)30933-9.

PERELAS A, SILVER R M, ARROSSI A V, et al . Systemic sclerosis-associated interstitial lung disease[J ] . Lancet Respir Med, 2020, 8(3): 304-320. DOI: 10.1016/S2213-2600(19)30480-1.

KHANNA D, NAGARAJA V, TSENG C H, et al . Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trials[J ] . Arthritis Res Ther, 2015, 17: 372. DOI: 10.1186/s13075-015-0872-2.

DISTLER O, HIGHLAND K B, GAHLEMANN M, et al . Nintedanib for systemic sclerosis-associated interstitial lung disease[J ] . N Engl J Med, 2019, 380(26): 2518-2528. DOI: 10.1056/NEJMoa1903076.

JORGENSEN S C J, TSE C L Y, BURRY L, et al . Baricitinib: a review of pharmacology, safety, and emerging clinical experience in COVID-19[J ] . Pharmacotherapy, 2020, 40(8): 843-856. DOI: 10.1002/phar.2438.

ASSADIASL S, FATAHI Y, MOSHARMOVAHED B, et al . Baricitinib: from rheumatoid arthritis to COVID-19[J ] . J Clin Pharmacol, 2021, 61(10): 1274-1285. DOI: 10.1002/jcph.1874.

KALIL A C, PATTERSON T F, MEHTA A K, et al . Baricitinib plus remdesivir for hospitalized adults with covid-19[J ] . N Engl J Med, 2021, 384(9): 795-807. DOI: 10.1056/NEJMoa2031994.

HVBNER R H, GITTER W, EL MOKHTARI N E, et al . Standardized quantification of pulmonary fibrosis in histological samples[J ] . Biotechniques, 2008, 44(4): 507-511, 514-517. DOI: 10.2144/000112729.

RUAN H, LUAN J Y, GAO S Y, et al . Fedratinib attenuates bleomycin-induced pulmonary fibrosis via the JAK2/STAT3 and TGF-β1 signaling pathway[J ] . Molecules, 2021, 26(15): 4491. DOI: 10.3390/molecules26154491..

EID R A, ALKHATEEB M A, EL-KOTT A F, et al . A high-fat diet rich in corn oil induces cardiac fibrosis in rats by activating JAK2/STAT3 and subsequent activation of ANG Ⅱ/TGF-1β/Smad3 pathway: the role of ROS and IL-6 trans-signaling[J ] . J Food Biochem, 2019, 43(8): e12952. DOI: 10.1111/jfbc.12952.

WANG S H, LIU M F, LI X J, et al . Canonical and noncanonical regulatory roles for JAK2 in the pathogenesis of rheumatoid arthritis-associated interstitial lung disease and idiopathic pulmonary fibrosis[J ] . FASEB J, 2022, 36(6): e22336. DOI: 10.1096/fj.202101436R.

MILARA J, HERNANDEZ G, BALLESTER B, et al . The JAK2 pathway is activated in idiopathic pulmonary fibrosis[J ] . Respir Res, 2018, 19(1): 24. DOI: 10.1186/s12931-018-0728-9.

周宪宾. 巨噬细胞M1/M2极化分型的研究进展[J]. 中国免疫学杂志, 2012, 28(10): 957-960. . DOI: 10.3969/j.issn.1000-484X.2012.10.022.

ZHOU X B. Research progress on M1/M2 polarization typing of macrophages[J]. Chin J Immunol, 2012, 28(10): 957-960. . DOI: 10.3969/j.issn.1000-484X.2012.10.022.

RUSSELL D G, HUANG L, VANDERVEN B C. Immunometabolism at the interface between macrophages and pathogens[J]. Nat Rev Immunol, 2019, 19(5): 291-304. DOI: 10.1038/s41577-019-0124-9.

WANG L X, ZHANG S X, WU H J, et al . M2b macrophage polarization and its rolesin diseases[J ] . J Leukoc Biol, 2019, 106(2): 345-358. DOI: 10.1002/JLB.3RU1018-378RR.

蔡泽慧, 赵鹏, 张蓝熙, 等. 巨噬细胞活化参与肺纤维化机制研究进展[J]. 中国老年学杂志, 2022, 42(15): 3853-3857. DOI: 10.3969/j.issn.1005-9202.2022.15.061.

CAI Z H,ZHAO P, ZHANG L X, et al . Research progress on the mechanism of macrophage activation participating in pulmonary fibrosis[J ] . Chin J Gerontol, 2022, 42(15): 3853-3857. DOI: 10.3969/j.issn.1005-9202.2022.15.061.

WANG L, ZHANG H S, SUN L Y, et al . Manipulation of macrophage polarization by peptide-coated gold nanoparticles and its protective effects on acute lung injury[J ] . J Nanobiotechnology, 2020, 18(1): 38. DOI:10.1186/s12951-020-00593-7.

石小云. M2巨噬细胞在脂多糖诱导肺纤维化中的作用及机制[D]. 南昌: 南昌大学, 2021.

SHI X Y. Effects and mechanism of M2 macrophages on pulmonary fibrosis induced by lipopolysaccharide[D]. Nanchang: Nanchang University, 2021.

DONG J, MA Q. Macrophage polarization and activation at the interface of multi-walled carbon nanotube-induced pulmonary inflammation and fibrosis[J]. Nanotoxicology, 2018, 12(2): 153-168. DOI: 10.1080/17435390.2018.1425501.

LIANG Y B, TANG H, CHEN Z B, et al . Downregulated SOCS 1 expression activates the JAK1/STAT1 pathway and promotes polarization of macrophages into M1 type[J ] . Mol Med Rep, 2017, 16(5): 6405-6411. DOI: 10.3892/mmr.2017.7384..

周琦, 孙慧娟, 于栋华, 等. 巨噬细胞M1/M2型极化在不同疾病中的作用机制[J]. 中国药理学通报, 2020, 36(11): 1502-1506. DOI: 10.3969/j.issn.1001-1978.2020.11.005.

ZHOU Q, SUN H J, YU D H, et al . Mechanisms of M1/M2 macrophage polarization in different diseases[J ] . Chin Pharmacol Bull, 2020, 36(11): 1502-1506. DOI: 10.3969/j.issn.1001-1978.2020.11.005.

SPALINGER M R, SAYOC-BECERRA A, ORDOOKHANIAN C, et al . The JAK inhibitor tofacitinib rescues intestinal barrier defects caused by disrupted epithelial-macrophage interactions[J ] . J Crohns Colitis, 2021, 15(3): 471-484. DOI: 10.1093/ecco-jcc/jjaa182.

RUNTSCH M C, ANGIARI S, HOOFTMAN A, et al . Itaconate and itaconate derivatives target JAK1 to suppress alternative activation of macrophages[J ] . Cell Metab, 2022, 34(3): 487-501. e8. DOI: 10.1016/j.cmet.2022.02.002.

SHAN X, HU P, NI L, et al . Serine metabolism orchestrates macrophage polarization by regulating the IGF1-p38 axis[J ] . Cell Mol Immunol, 2022, 19(11): 1263-1278. DOI: 10.1038/s41423-022-00925-7.

ZHU H, JIAN Z H, ZHONG Y, et al . Janus kinase inhibition ameliorates ischemic stroke injury and neuroinflammation through reducing NLRP3 inflammasome activation via JAK2/STAT3 pathway inhibition[J ] . Front Immunol, 2021, 12: 714943. DOI: 10.3389/fimmu.2021.714943..

XU M, LI X Y, SONG L C. Baicalin regulates macrophages polarization and alleviates myocardial ischaemia/reperfusion injury via inhibiting JAK/STAT pathway[J]. Pharm Biol, 2020, 58(1): 655-663. DOI: 10.1080/13880209.2020.1779318.

BUECHLER M B, FU W X, TURLEY S J. Fibroblast-macrophage reciprocal interactions in health, fibrosis, and cancer[J]. Immunity, 2021, 54(5): 903-915. DOI: 10.1016/j.immuni.2021.04.021.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

缺氧通过驱动M1巨噬细胞极化诱发睾丸间质细胞溶酶体依赖性死亡导致生精功能受损

蛋白磷酸酶2A促进线粒体自噬减轻果糖诱导的M2型巨噬细胞线粒体氧化损伤

INKA2-AS1促进肝细胞癌迁移、侵袭和巨噬细胞相关免疫抑制机制研究

铁抑素-1通过抑制肺上皮细胞铁死亡减轻高原低氧肺损伤炎症反应

右美托咪定对脓毒症大鼠肠道屏障功能的保护作用